GLP2-T (Tirzepatide)

Overview

Tirzepatide (LY3298176), commonly referred to as GLP2-T in research circles, is a dual-agonist peptide that targets both GLP-1 and GIP receptors. Originally developed for type 2 diabetes research, it has attracted significant attention for its potent effects on body composition and appetite regulation.

Mechanism of Action

Tirzepatide binds to and activates both GLP-1 and GIP receptors. GLP-1 activation reduces appetite through central nervous system satiety pathways and slows gastric emptying. GIP receptor activation improves insulin secretion, enhances lipid handling, and may contribute to adipose tissue remodeling. The dual mechanism creates overlapping metabolic benefits that amplify each other.

Research Context

Published trial data demonstrated substantial body weight reductions, with some cohorts achieving mean weight loss exceeding 20% of baseline body weight. Tirzepatide has also shown improvements in glycemic control, lipid profiles, and blood pressure. The GIP component differentiates it from pure GLP-1 agonists and may contribute to its enhanced efficacy.

Key Research Areas

Considerations for Researchers

Wide price variance across vendors reflects differences in purity, source, and batch size. Researchers should prioritize vendors with transparent COA documentation and batch-specific HPLC data. Store lyophilized powder at -20C for long-term stability.